Scholar Rock Holding (SRRK) Net Income (2017 - 2026)
Scholar Rock Holding's quarterly Net Income came in at -$101.4 million in Q1 2026, down 35.76% year-on-year from -$157.8 million in Q1 2025, and down 11.53% quarter-over-quarter from -$90.9 million in Q4 2025.
Scholar Rock Holding has reported Net Income for 10 years, with the latest figure at -$101.4 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income fell 35.76% year-over-year to -$101.4 million; the trailing twelve-month figure through Mar 2026 stood at -$404.3 million (down 53.13% YoY), and the FY2025 full-year result was -$205000.0, up 99.92% from the prior year.
- Net Income for Q1 2026 stood at -$101.4 million, down from -$90.9 million in the prior quarter.
- The five-year high for Net Income was -$6.9 million in Q1 2022, with the low at -$109.9 million in Q2 2025.
- Average Net Income over 5 years is -$60.6 million, with a median of -$56.8 million recorded in 2024.
- Year-over-year, Net Income jumped 74.52% in 2022 and sank 484.29% in 2023.
- Tracing SRRK's Net Income over 5 years: stood at -$40.4 million in 2022, then retreated by 18.81% to -$48.0 million in 2023, then tumbled by 38.33% to -$66.4 million in 2024, then sank by 36.82% to -$90.9 million in 2025, then retreated by 11.53% to -$101.4 million in 2026.
- The last three Net Income figures came in at -$101.4 million (Q1 2026), -$90.9 million (Q4 2025), and -$102.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | -101.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -101.38 Mn |
| Dec 31, 2025 | -90.90 Mn |
| Sep 30, 2025 | -102.15 Mn |
| Jun 30, 2025 | -109.90 Mn |
| Mar 31, 2025 | -74.68 Mn |
| Dec 31, 2024 | -66.44 Mn |
| Sep 30, 2024 | -64.44 Mn |
| Jun 30, 2024 | -58.49 Mn |
| Mar 31, 2024 | -56.83 Mn |
| Dec 31, 2023 | -48.03 Mn |
| Sep 30, 2023 | -43.67 Mn |
| Jun 30, 2023 | -39.08 Mn |
| Mar 31, 2023 | -40.51 Mn |
| Dec 31, 2022 | -40.43 Mn |
| Sep 30, 2022 | -43.86 Mn |
| Jun 30, 2022 | -43.15 Mn |
| Mar 31, 2022 | -6.93 Mn |
| Dec 31, 2021 | -35.36 Mn |
| Sep 30, 2021 | -37.08 Mn |
| Jun 30, 2021 | -30.27 Mn |
| Mar 31, 2021 | -27.21 Mn |
| Dec 31, 2020 | -26.10 Mn |
| Sep 30, 2020 | -23.62 Mn |
| Jun 30, 2020 | -19.46 Mn |
| Mar 31, 2020 | -17.69 Mn |
| Dec 31, 2019 | -12.35 Mn |
| Sep 30, 2019 | -17.11 Mn |
| Jun 30, 2019 | -13.39 Mn |
| Mar 31, 2019 | -11.70 Mn |
| Dec 31, 2018 | -15.56 Mn |
| Sep 30, 2018 | -11.23 Mn |
| Jun 30, 2018 | -14.88 Mn |
| Mar 31, 2018 | -9.02 Mn |
| Dec 31, 2017 | -8.46 Mn |
| Sep 30, 2017 | -5.94 Mn |
| Jun 30, 2017 | -5.89 Mn |